Login to Your Account



VYXEOS-LIKE HOPES GRANDIOSE? CAN SAPA REMIT IN THE INDUCTION-UNFIT?

Ahem: SEAMLESS aside, Cyclacel well enough as investors knit brows over odds in AML study

By Randy Osborne
Staff Writer

Friday, August 12, 2016

Even if Wall Street scratches off the soon-to-report, longshot phase III SEAMLESS trial in acute myeloid leukemia (AML), Cyclacel Pharmaceuticals Inc. may have value aplenty in an early stage pair of other clinical programs. But home-run hopes die hard and biotech is full of surprises – such as Vyxeos, the late-stage AML winner in March for Celator Pharmaceuticals Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription